

# Yoko Katsuno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2580153/publications.pdf>

Version: 2024-02-01

8  
papers

1,292  
citations

1163117

8  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

2512  
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF- $\beta$ 2 signaling and epithelial-mesenchymal transition in cancer progression. <i>Current Opinion in Oncology</i> , 2013, 25, 76-84.	2.4	698
2	Chronic TGF- $\beta$ 2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. <i>Science Signaling</i> , 2019, 12, .	3.6	166
3	Intracellular and extracellular TGF- $\beta$ 2 signaling in cancer: some recent topics. <i>Frontiers of Medicine</i> , 2018, 12, 387-411.	3.4	108
4	Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumorigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF- $\beta$ 2. <i>Journal of Pathology</i> , 2012, 228, 391-404.	4.5	91
5	Epithelial plasticity, epithelial-mesenchymal transition, and the TGF- $\beta$ 2 family. <i>Developmental Cell</i> , 2021, 56, 726-746.	7.0	82
6	Smad3-mediated recruitment of the methyltransferase SETDB1/ESET controls <i>Snail1</i> expression and epithelial-mesenchymal transition. <i>EMBO Reports</i> , 2018, 19, 135-155.	4.5	58
7	Smad4 Decreases the Population of Pancreatic Cancer-Initiating Cells through Transcriptional Repression of ALDH1A1. <i>American Journal of Pathology</i> , 2015, 185, 1457-1470.	3.8	50
8	ShcA Protects against Epithelial-Mesenchymal Transition through Compartmentalized Inhibition of TGF- $\beta$ 2-Induced Smad Activation. <i>PLoS Biology</i> , 2015, 13, e1002325.	5.6	39